Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Oncoimmunology. 2018 Aug 15;7(10):e1490856. doi: 10.1080/2162402X.2018.1490856. eCollection 2018.

CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy.

Author information

1
Cancer Gene Therapy Group, University of Helsinki, Helsinki, Finland.
2
TILT Biotherapeutics Ltd, Helsinki, Finland.
3
Division of Urology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
4
Department of Pathology, University of Washington, Seattle, WA, USA.
5
Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands.
6
Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland.
7
Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.

Abstract

Dendritic cells (DCs) are crucial players in promoting immune responses. Logically, adoptive DC therapy is a promising approach in cancer immunotherapy. One of the major obstacles in cancer immunotherapy in general is the immunosuppressive tumor microenvironment, which hampers the maturation and activation of DCs. Therefore, human clinical outcomes with DC therapy alone have been disappointing. In this study, we use fully serotype 3 oncolytic adenovirus Ad3-hTERT-CMV-hCD40L, expressing human CD40L, to modulate the tumor microenvironment with subsequently improved function of DCs. We evaluated the synergistic effects of Ad3-hTERT-CMV-hCD40L and DCs in the presence of human peripheral blood mononuclear cells ex vivo and in vivo. Tumors treated with Ad3-hTERT-CMV-hCD40L and DCs featured greater antitumor effect compared with unarmed virus or either treatment alone. 100% of humanized mice survived to the end of the experiment, while mice in all other groups died by day 88. Moreover, adenovirally-delivered CD40L induced activation of DCs, leading to induction of Th1 immune responses. These results support clinical trials with Ad3-hTERT-CMV-hCD40L in patients receiving DC therapy.

KEYWORDS:

Ad3; CD40L; Dendritic cells; T-cells; oncolytic adenovirus

PMID:
30386680
PMCID:
PMC6207416
[Available on 2019-08-15]
DOI:
10.1080/2162402X.2018.1490856

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center